AU2001254937A1 - (e)-7(4-fluorophenyl)-6isopropyl2-mesylaminopyrimidin-5-y)-( 3r,5s)-dihydroxyhept-6-enoic acid. - Google Patents

(e)-7(4-fluorophenyl)-6isopropyl2-mesylaminopyrimidin-5-y)-( 3r,5s)-dihydroxyhept-6-enoic acid.

Info

Publication number
AU2001254937A1
AU2001254937A1 AU2001254937A AU5493701A AU2001254937A1 AU 2001254937 A1 AU2001254937 A1 AU 2001254937A1 AU 2001254937 A AU2001254937 A AU 2001254937A AU 5493701 A AU5493701 A AU 5493701A AU 2001254937 A1 AU2001254937 A1 AU 2001254937A1
Authority
AU
Australia
Prior art keywords
mesylaminopyrimidin
dihydroxyhept
fluorophenyl
enoic acid
enoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001254937A
Inventor
Eva Maria Lenz
Paul John Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2001254937A1 publication Critical patent/AU2001254937A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AU2001254937A 2000-05-10 2001-05-04 (e)-7(4-fluorophenyl)-6isopropyl2-mesylaminopyrimidin-5-y)-( 3r,5s)-dihydroxyhept-6-enoic acid. Abandoned AU2001254937A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0011163 2000-05-10
GBGB0011163.3A GB0011163D0 (en) 2000-05-10 2000-05-10 Chemical compound
PCT/GB2001/001979 WO2001085702A1 (en) 2000-05-10 2001-05-04 (e)-7(4-fluorophenyl)-6isopropyl2-mesylaminopyrimidin-5-y)-(3r,5s)-dihydroxyhept-6-enoic acid.

Publications (1)

Publication Number Publication Date
AU2001254937A1 true AU2001254937A1 (en) 2001-11-20

Family

ID=9891244

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001254937A Abandoned AU2001254937A1 (en) 2000-05-10 2001-05-04 (e)-7(4-fluorophenyl)-6isopropyl2-mesylaminopyrimidin-5-y)-( 3r,5s)-dihydroxyhept-6-enoic acid.

Country Status (7)

Country Link
US (1) US20040006097A1 (en)
EP (1) EP1286971A1 (en)
JP (1) JP2003532715A (en)
AU (1) AU2001254937A1 (en)
CA (1) CA2404987A1 (en)
GB (1) GB0011163D0 (en)
WO (1) WO2001085702A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1301977C (en) * 2001-07-13 2007-02-28 阿斯特拉曾尼卡英国有限公司 Preparation of aminopyrimidine compounds
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
ATE448209T1 (en) 2002-12-16 2009-11-15 Astrazeneca Uk Ltd METHOD FOR PRODUCING PYRIMIDINE COMPOUNDS
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (en) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd CHEMICAL COMPOUNDS
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
GB0406757D0 (en) 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
GB0427491D0 (en) 2004-12-16 2005-01-19 Avecia Ltd Process and compounds
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
HU227120B1 (en) * 2005-05-26 2010-07-28 Richter Gedeon Nyrt Process for the preparation of calcium salt of rosuvastatin via new intermediates
CN103936680B (en) * 2014-04-18 2016-08-24 润泽制药(苏州)有限公司 The preparation method of rosuvastain calcium known impurities
CN108707118A (en) * 2018-06-22 2018-10-26 江苏阿尔法药业有限公司 A kind of preparation method of demethyl rosuvastain calcium

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (en) * 1991-07-01 1997-09-03 塩野義製薬株式会社 Pyrimidine derivatives
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them

Also Published As

Publication number Publication date
CA2404987A1 (en) 2001-11-15
US20040006097A1 (en) 2004-01-08
JP2003532715A (en) 2003-11-05
WO2001085702A1 (en) 2001-11-15
EP1286971A1 (en) 2003-03-05
GB0011163D0 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
AU2001237039A1 (en) Message router
AU6497600A (en) Peracid forming system, peracid forming composition, and methods for making and using
AU2001290539A1 (en) Additive-assisted, cerium-based, corrosion-resistant e-coating
AP2003002925A0 (en) Tobacco biomas utilization.
AU2001265089A1 (en) Rc-timer scheme
AU2002313347A1 (en) I.S. Glass Forming Machine
AU2001254937A1 (en) (e)-7(4-fluorophenyl)-6isopropyl2-mesylaminopyrimidin-5-y)-( 3r,5s)-dihydroxyhept-6-enoic acid.
AU2001259186A1 (en) Ticketless admission system
AU2002228806A1 (en) Trocess for making 5-cyanovaleric acid, adipic acid or dimethyl adidpate
AU1254301A (en) Multiple driver, resonantly-coupled loudspeaker
AU1194201A (en) Fluorotellurite, amplifier glasses
AUPQ870300A0 (en) Mbds, mbds ii, ti, b.cp.
MXPA03004331A (en) Novel carbapenem derivatives.
MXPA01012693A (en) Production for tequila.
AU2001293697A1 (en) N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives
AU2003254555A1 (en) S. aureus antigene
AU2002363942A1 (en) Optimizations for live event, real-time, 3d object traking
AU2003230738A1 (en) Active-loop, spatially-combined amplifier
AU2001267000A1 (en) Improved phosphating operation
AU2002952987A0 (en) Reply system
AUPR246301A0 (en) F.l.o.e.s, s.p.l.s.d
AU2002313984A1 (en) I.S. Glass Forming Machine
AU2176401A (en) ILK-2, an integtrin-linked kinase
AU2001238143A1 (en) Tumor suppressor gene, p47ing3
AU2001274091A1 (en) Method for producing optionally substituted aliphatic, aromatic or heteraromaticaldehydes